Digital health innovator, Gendius, a Manchester-based start-up using AI technology to measure and improve outcomes for people with diabetes, has been ranked 21st in the annual BusinessCloud MedTech 50 list. The MedTech 50 rankings highlight the UK’s most innovative start-ups, scaleups and established firms helping to diagnose and treat existing conditions.
Gendius CEO, Rory Cameron, comments, “We believe that our AI-driven risk prediction technology is going to be a game-changer for diabetes management, so it’s great to have that recognised in this year’s MedTech 50 rankings. We have really focused on developing technology that solves problems for clinicians and improves outcomes for patients, and it is this kind of technology that is going to drive long-term change in the way that we use healthcare technology.”
Gendius’s AI-driven platform, Intellin®, is designed to help people with diabetes to actively track and monitor their condition. Intellin® features both a user mobile app, and a healthcare provider dashboard. Through the user app, Intellin® allows people with diabetes to plan ahead by forecasting their risk factors for developing complications, such as chronic kidney disease or diabetic foot ulcer.
The web-based dashboard interfaces with the user app and enables healthcare providers to remotely monitor their patients’ disease management. To date, the Intellin® user app has been downloaded over 570,000 times and it has over 60,000 monthly active users.
Identifying and treating diabetes complications early has been highlighted as a key way of improving outcomes for people with diabetes. Diabetes is the most common cause of end-stage kidney failure in the UK, and it doubles the risk of cardiovascular disease, including heart attack, heart failure, angina, and stroke. It is estimated that treatment of diabetes and diabetes complications accounts for 9% of the total NHS budget, and that 10% of NHS hospital beds are occupied by people with diabetes.